Patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least  days after completion of treatment.
Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least  days after completion of treatment. Male patients must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least  days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator or a designated associate.
Pregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and for  months afterwards; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within  days from starting the conditioning chemotherapy; the definition of effective contraception will be based on the judgment of the study investigators
Pregnancy or breastfeeding. Female subjects must be surgically sterile or be postmenopausal,or must agree to use effective contraception during the period of therapy. All female subjects with reproductive potential must have a negative pregnancy test (serum) prior to enrollment. Male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
For patients post pubertal: Female patients must agree to use effective contraception during the period of the trial and for at least  days after completion of treatment. Male patients must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least  days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator.
Pregnant and/or breastfeeding; women of childbearing potential must have a negative serum pregnancy test within  days of study entry; female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least  days after completion of treatment
Pregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and for  months afterwards; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within  days from starting the conditioning chemotherapy; the definition of effective contraception will be based on the judgment of the study investigators
Pregnancy or breastfeeding - Female patients must be surgically sterile (i.e., ? weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) or be postmenopausal, or must agree to use effective contraception during the study and for  months following last dose of carotuximab (TRC). All female patients of reproductive potential must have a negative pregnancy test (serum or urine) within  days prior to study treatment. Male patients must be surgically sterile or must agree to use effective contraception during the study and for  months following last dose of carotuximab (TRC). The definition of effective contraception is provided in Section .. of this protocol.
Patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least  days after completion of treatment
Pregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and  months after; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within  hours from starting the conditioning chemotherapy; the definition of effective contraception will be based on the judgment of the study investigators; patients who are breastfeeding are not allowed on study
Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least  days after completion of treatment.
Male patients sexually active with a woman of childbearing potential must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least  days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator.
Pregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and  months after; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within  hours from starting the conditioning chemotherapy
Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least  days after completion of treatment; male patients must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least  days after completion of treatment; the decision of effective contraception will be based on the judgment of the principal investigator or a designated associate
Be a pregnant or breast-feeding woman; female patients of childbearing potential must agree to use effective contraception, must be surgically sterile, or must be postmenopausal; male patients must agree to use effective contraception or be surgically sterile; barrier methods are a recommended form of contraception
Pregnancy or breast-feeding; female patients must be surgically sterile or be post-menopausal, or must agree to use effective contraception during the period of therapy; all female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment; male patients must be surgically sterile or must agree to use effective contraception during the period of therapy; the definition of effective contraception will be based on the judgment of the principal investigator or a designated associate
Female patients must be at least  year postmenopausal or surgically sterile; or must agree to use a medically acceptable form of contraception
Female patients should not be pregnant or breast-feeding; female patients, if not postmenopausal (<  months of amenorrhea) or surgically sterile, should agree to use effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) during the study and for a period of at least  months following the last administration of study drugs; female patients with an intact uterus (unless amenorrheic for the last  months) must have a negative serum pregnancy test within  days prior to randomization into the study
Pregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and  months after; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within  days from starting the conditioning chemotherapy; the definition of effective contraception will be based on the judgment of the study investigators
Patients or their partners must be surgically sterile or must agree to use effective contraception while receiving study treatment and for at least  months thereafter; the definition of effective contraception should be in agreement with local regulation and based on the judgment of the principal investigator or a designated associate
Pregnant and/or breastfeeding; women of childbearing potential must have a negative serum pregnancy test within  days of study entry; female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraceptive during the period of the trial and for at least  days after completion of treatment; the decision of effective contraception will be based on the judgment of the principal investigator or a designated associate
Pregnancy or breast-feeding; patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy; the definition of effective contraception will be based on the judgment of the MSKCC and participating site principal investigator (PI); male patients must be surgically sterile or agree to use effective contraception
Pregnancy or breastfeeding. Female patients must be surgically sterile (i.e.: hysterectomy) or be postmenopausal, or must agree to use effective contraception during the study and for  months following last dose of TRC. All female patients of reproductive potential must have a negative pregnancy test (serum or urine) within  days prior to first dose. Male patients must be surgically sterile or must agree to use effective contraception during the study and for  months following last dose of TRC. The definition of effective contraception will be based on the judgment of the Principal Investigator or a designated associate.
Pregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and  months after; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within  days from starting the conditioning chemotherapy; the definition of effective contraception will be based on the judgment of the study investigators
Pregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and  months after; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within  days from starting the conditioning chemotherapy; the definition of effective contraception will be based on the judgment of the study investigators
Pregnancy, lactation, or breast-feeding; patients must be surgically sterile, postmenopausal, or must agree to use effective contraception during the period of therapy and for  months after the last dose of atezolizumab; the definition of effective contraception will be based on the judgment of the principal investigator or a designated associate; male patients must be surgically sterile or agree to use effective contraception; male patients will be encouraged to notify the study team if their female partner becomes pregnant while on study
Pregnancy or breastfeeding; female subjects must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy; all female subjects with reproductive potential must have a negative pregnancy test (serum) prior to enrollment; male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy; the definition of effective contraception will be based on the judgment of the principal investigator or a designated associate
Pregnancy or breast feeding; patients must be surgically sterile, postmenopausal, or agree to use effective contraception during the period of therapy; the definition of effective contraception will be based on the judgement of the principal investigator or a designated associate; male patients must be surgically sterile or agree to effective contraception; female patients of child bearing potential (ages -) must have a negative beta-human chorionic gonadotropin (B-HCG) pregnancy test documented within  days prior to registration
Pregnancy or breast-feeding; patients must be surgically sterile, postmenopausal, or must agree to use effective contraception during the period of therapy; the definition of effective contraception will be based on the judgment of the principal investigator or a designated associate; male patients must be surgically sterile or agree to use effective contraception
Patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy and for two () months following the last dose of panitumumab; the definition of effective contraception will be based on the judgment of the principal investigator or a designated associate; male patients must be surgically sterile or agree to use effective contraception
Males, unless surgically sterile, must use  effective methods of contraception with a female partner and must agree to continue using such contraception for  days after the last dose of MEDI
Male subjects must be surgically sterile or agree to use effective contraception starting at the first dose of chemotherapy and for  months thereafter (if indicated in the country specific monograph/label for cyclophosphamide).
Women who are pregnant or breast-feeding; female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy; a negative pregnancy test is required within  hours of administration of radiotracer and study initiation for women of childbearing age and potential
